Bipinor Plus5 mg+12.5 mg

Bipinor Plus is a fixed-dose combination indicated for the treatment of hypertension (high blood pressure), used to lower blood pressure in adults.

• Established/approved use: Treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled on monotherapy with either a beta-blocker or a thiazide diuretic alone, or as an alternative to individual titration of the two components.
• Combination-therapy requirement: Bipinor Plus is not intended for initial therapy in patients whose blood pressure can be controlled on a single agent; it is generally used once patients have been assessed to require more than one class of antihypertensive.
• Guideline context: Combining a beta-1 selective blocker with a thiazide diuretic is a recognized guideline-supported strategy for achieving blood pressure targets when monotherapy is insufficient.

Bipinor Plus lowers blood pressure only; it does not treat the underlying cause of hypertension and does not replace lifestyle measures (diet, weight control, exercise, reduced salt intake) recommended alongside drug therapy.

Each tablet of Nebivolol + Hydrochlorothiazide contains two active ingredients in fixed combination:

• Nebivolol (as nebivolol hydrochloride) — a beta-1 selective adrenergic receptor blocker with additional nitric-oxide-mediated vasodilating activity.
• Hydrochlorothiazide — a thiazide-class diuretic.

Common strengths available in the market include nebivolol 5 mg with hydrochlorothiazide 12.5 mg per tablet; exact strengths and available brands can vary, so patients should always check the specific product label dispensed to them.

Bipinor Plus is an oral fixed-dose combination antihypertensive medicine that pairs a cardioselective beta-blocker with a thiazide diuretic in a single tablet. It is used once daily to help patients reach blood pressure goals with a single pill instead of taking two separate tablets.

By combining two complementary mechanisms of blood pressure lowering, Bipinor Plus can achieve greater blood pressure reduction than either component used alone, while allowing lower doses of each ingredient, which may reduce dose-related side effects.

Bipinor Plus belongs to the therapeutic class of antihypertensive combination agents, specifically a beta-1 selective adrenergic blocker combined with a thiazide diuretic. It is classified under cardiovascular drugs used for the management of high blood pressure.

Nebivolol + Hydrochlorothiazide combines two agents with complementary and additive antihypertensive mechanisms:

• Nebivolol is a highly beta-1 selective adrenergic receptor blocker at usual doses. It reduces heart rate and cardiac output, and also stimulates endothelial nitric oxide release, producing a mild vasodilating effect that helps lower peripheral vascular resistance. It has minimal effect on beta-2 receptors at recommended doses.
• Hydrochlorothiazide is a thiazide diuretic that acts on the distal convoluted tubule of the nephron, inhibiting sodium and chloride reabsorption. This increases excretion of sodium, chloride, and water, reducing plasma and extracellular fluid volume, which lowers blood pressure. With continued use, a component of blood-pressure lowering is also attributed to reduced peripheral vascular resistance.

Together, the reduced cardiac workload from beta-1 blockade and the volume/vascular effects of the diuretic produce a more pronounced and sustained reduction in blood pressure than either drug alone.

Pharmacokinetics (brief): Nebivolol undergoes extensive hepatic metabolism via CYP2D6; metabolizer status (extensive vs. poor) affects plasma levels, though clinical dosing is generally similar. Hydrochlorothiazide is not significantly metabolized and is excreted largely unchanged by the kidneys, with a plasma half-life of roughly 6–15 hours.

Bipinor Plus tablets should be swallowed whole with a glass of water, with or without food, once daily. Do not crush or chew the tablet unless specifically advised by a physician or pharmacist. Take the dose at a consistent time each day to maintain steady blood pressure control.

Bipinor Plus has clinically significant interactions related to both of its components:

• Other antihypertensives, nitrates, or vasodilators: Additive blood-pressure-lowering and hypotensive effects; dose adjustment may be needed.
• Calcium channel blockers (e.g., verapamil, diltiazem): Increased risk of bradycardia, AV conduction disturbances, and hypotension due to additive effects on the heart's electrical conduction; concurrent use requires caution and monitoring.
• Digoxin: Beta-blockade can have additive effects on AV nodal conduction time and heart rate; thiazide-induced hypokalemia can increase the risk of digoxin toxicity. Monitor heart rate and electrolytes.
• CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine, propafenone): Can increase plasma levels of nebivolol, potentially increasing beta-blocking effects; dose caution advised.
• Clonidine: If both are to be discontinued, the beta-blocker component should be withdrawn gradually before clonidine is stopped, to avoid rebound hypertension.
• NSAIDs: May reduce the antihypertensive and diuretic effect of Bipinor Plus and increase the risk of renal impairment, especially in volume-depleted patients.
• Lithium: Thiazides reduce renal lithium clearance, increasing the risk of lithium toxicity; concurrent use is generally avoided or requires close monitoring.
• Insulin and oral antidiabetic drugs: Beta-blockade can mask signs of hypoglycemia (such as tachycardia); the thiazide component can raise blood glucose. Blood sugar should be monitored closely.
• Corticosteroids and ACTH: May enhance electrolyte depletion (particularly hypokalemia) caused by the thiazide component.
• Alcohol, barbiturates, or opioids: May potentiate orthostatic (postural) hypotension.
• Cholestyramine or colestipol: Can reduce absorption of hydrochlorothiazide; separate dosing times are advised.

Always inform the physician or pharmacist of all prescription, over-the-counter, and herbal products being used before starting Bipinor Plus.

Side effects of Bipinor Plus arise from either the beta-blocker or the thiazide diuretic component.

Common side effects

• Headache and dizziness
• Fatigue or tiredness
• Bradycardia (slow heart rate)
• Cold hands or feet
• Nausea
• Increased urination
• Muscle cramps

Less common but important side effects

• Electrolyte disturbances (low potassium, low sodium, low magnesium)
• Orthostatic (postural) hypotension, especially in the elderly or volume-depleted patients
• Worsening of blood glucose control in patients with diabetes
• Increased blood uric acid levels or gout flare
• Photosensitivity (increased skin sensitivity to sunlight)
• Erectile dysfunction
• Shortness of breath or bronchospasm in susceptible individuals

Patients should seek prompt medical attention for signs of a serious allergic reaction, severe dizziness or fainting, very slow heartbeat, significant swelling, or difficulty breathing.

Pregnancy: Bipinor Plus should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Beta-blockers used late in pregnancy have been associated with fetal/neonatal bradycardia and hypoglycemia, and the thiazide component can cross the placenta and has been associated with neonatal jaundice, thrombocytopenia, and reduced placental perfusion. A physician should always be consulted before use in pregnancy, and alternative agents are generally preferred where blood pressure control is needed during pregnancy.

Lactation: Both nebivolol and hydrochlorothiazide pass into breast milk. Thiazide diuretics may also reduce milk production. Bipinor Plus should be used during breastfeeding only under medical supervision, weighing the benefit to the mother against potential risk to the nursing infant; the infant should be monitored for signs such as poor feeding or unusual drowsiness if the mother uses this medicine.

Consult a physician before using Bipinor Plus if pregnant, planning pregnancy, or breastfeeding.

• Do not stop abruptly: Sudden discontinuation of Bipinor Plus, particularly in patients with coronary artery disease, can precipitate rebound hypertension, worsening angina, myocardial infarction, or serious arrhythmias. The dose should be tapered gradually over one to two weeks under medical supervision, even in patients without overt heart disease.
• Cardiac conduction and heart failure: Use with caution in patients with first-degree AV block or compensated heart failure; the beta-blocker component can further slow conduction or worsen borderline cardiac function.
• Electrolyte and fluid balance: The thiazide component can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia. Periodic monitoring of serum electrolytes is recommended, especially with prolonged use, vomiting, diarrhea, or concurrent diuretic/corticosteroid use.
• Diabetes mellitus: Use with caution; the thiazide component may worsen glycemic control, and the beta-blocker component can mask warning signs of hypoglycemia such as rapid heartbeat. Blood glucose should be monitored regularly.
• Bronchospastic disease (asthma/COPD): Even beta-1 selective agents like the nebivolol component can, in some individuals, precipitate bronchospasm; use with caution and only if no suitable alternative exists.
• Peripheral vascular disease: Beta-blockers may aggravate symptoms of peripheral arterial circulatory disorders.
• Thyroid disease: Beta-blockade may mask signs of hyperthyroidism (such as tachycardia); abrupt withdrawal may worsen symptoms or precipitate thyroid storm in susceptible patients.
• Renal impairment: Thiazides may precipitate azotemia in patients with significant renal disease; use with caution and monitor renal function.
• Hepatic impairment: Use with caution in mild-to-moderate hepatic impairment; contraindicated in severe hepatic impairment (see Contraindications). Thiazides can precipitate hepatic coma in patients with impaired liver function or progressive liver disease.
• Gout: The thiazide component may raise uric acid levels and precipitate gout attacks in susceptible individuals.
• Photosensitivity and skin reactions: Thiazides have been associated with photosensitivity reactions; use sun protection. Long-term thiazide use has also been associated in some studies with a modestly increased risk of certain non-melanoma skin cancers; discuss any new or changing skin lesions with a physician.
• Surgery/anesthesia: Inform the anesthesiologist that the patient is taking Bipinor Plus, as continued beta-blockade requires careful management during major surgery.
• Acute angle-closure glaucoma/acute myopia: Rarely, sulfonamide-derived drugs such as the hydrochlorothiazide component have been associated with acute transient myopia and acute angle-closure glaucoma; seek urgent care for sudden eye pain or visual disturbance.

Overdose of Bipinor Plus may cause severe bradycardia, hypotension, bronchospasm, acute heart failure, and hypoglycemia (from the beta-blocker component), together with dehydration, electrolyte depletion, and lethargy or confusion (from the thiazide diuretic component). In severe cases, cardiac arrest is possible.

If an overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Do not attempt to treat an overdose at home. Bring the medicine packaging with you to the hospital if possible. Management will be supportive and may include cardiac monitoring, IV fluids, and specific treatments administered by medical professionals under close supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Bipinor Plus can be used in elderly patients; however, they may be more sensitive to blood-pressure-lowering and electrolyte effects. Start with caution and monitor renal function, electrolytes, and blood pressure closely, particularly for orthostatic hypotension and falls risk.

Renal impairment: Use with caution; thiazides are generally less effective and may not be appropriate in patients with significantly reduced kidney function (see Dosage and Administration).

Hepatic impairment: Contraindicated in severe hepatic impairment; use with caution and close monitoring in mild-to-moderate impairment.

Diabetic patients: Use with caution due to potential effects on blood glucose control and masking of hypoglycemia symptoms (see Precautions and Warnings).

Pediatric patients: Safety and efficacy have not been established in children and adolescents; Bipinor Plus is not recommended for use in this population (see Pediatric Uses).

Bipinor Plus is generally used long-term for ongoing control of high blood pressure, as hypertension is a chronic condition requiring continuous management. Treatment duration should be determined by the prescribing physician based on blood pressure response, and the medicine should not be stopped without medical advice, even if blood pressure appears well controlled, since discontinuation can cause rebound effects.

Antihypertensive combination; beta-1 selective adrenergic blocker (nebivolol) plus thiazide diuretic (hydrochlorothiazide).

Nebivolol + Hydrochlorothiazide lowers blood pressure through two complementary mechanisms: the nebivolol component selectively blocks beta-1 adrenergic receptors in the heart, reducing heart rate and cardiac output, while also promoting nitric-oxide-mediated vasodilation that reduces peripheral resistance. The hydrochlorothiazide component inhibits sodium and chloride reabsorption in the distal renal tubule, increasing urinary excretion of sodium and water, which reduces circulating blood volume and, with continued use, peripheral vascular resistance. The combined effect is a greater and more sustained reduction in blood pressure than either agent alone.

The safety and efficacy of Bipinor Plus have not been established in pediatric patients (children and adolescents under 18 years of age). It is not recommended for use in this age group outside of specialist supervision. If blood pressure management is needed in a child or adolescent, a pediatric specialist should be consulted for age-appropriate treatment options.